Market Cap 372.39B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 20.46
Forward PE 14.56
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 5,385,000
Avg Vol 6,871,812
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 70%
Beta 0.32
Analysts Strong Sell
Price Target $251.03

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
UsingAGodAlgorithm
UsingAGodAlgorithm May. 16 at 10:54 PM
$SE (-75% from short entry) We are the best on ST as far as we have seen. Check our profile We also covered these names. $ABBV $PLTR $MU $MA
0 · Reply
Mike22332233
Mike22332233 May. 16 at 10:51 PM
$SLS Some think $40 Bil BO is silly ... really, FOR AN EFFECTIVE CURE FOR CANCER !!! ... and then across 20 other cancers with WT1 !!! Add in the SLS001 platform!!! ... KEYTRUDA has sales of $34 Bil per year and does NOT cure anything ... We will see how silly it is when $MRK, $ABBV and $PFE are in a bidding war to buy out $SLS ... Single BEST asymmetrical investment idea in my over 40 years investing ... ALL my profits from every other Special Situation Stock I have found (see my other posts) have been plowed back into more SLS ... If you agree with what I will say, then LIKE this and FOLLOW me 👉 @Mike22332233 ...
4 · Reply
Mike22332233
Mike22332233 May. 16 at 9:29 PM
$SLS PART 2 of 2 .. Even with the BAT arm at 14.7 mOS which is almost twice as long as should be expected … EFFECTIVELY, those getting GPS that had an immune response (80% of them) ARE NOT PASSING AWAY!!! ... GAME CHANGING FOR CANCER !!! When the trial ends at the 80th event, I believe you would have ALL 63 in the BAT Control arm passed away, AND ONLY 17 OF THE 63 GPS PATIENTS PASSED AWAY … 46 of the 63 will be alive and living into their 4th yr and some into their 5th year…. This has EFFECTIVELY STOPPED CANCER FROM KILLING THEM IN THIS TYPE OF CANCER !! ... There are an additional 20 or so Cancers with the WT1 within them … as I said before, likely $ABBV or $MEK or $PFE doing a BUY OUT WITHIN 3 months of the readout, and my MAXIMUM PRICE OF $150 to $175 (a $30 to $35 Billion valuation) for the BO may very well be much too low if the HR is GAME-CHANGING at 0.27-0.35 ... if so, expect a bidding war and final BO at $222 !!! ... If you agree then LIKE this and FOLLOW me 👉 @Mike22332233
3 · Reply
DonVigo
DonVigo May. 16 at 7:30 PM
$SLS $ABBV $BMY $MRK 40 billion? You must be brain dead. Is SLS peddling a cure for cancer or a treatment? Outrageous ...!
0 · Reply
DonVigo
DonVigo May. 16 at 7:22 PM
$SLS $ABBV $BMY $MRK That PR event may occur under the name of a different Company. Prove me wrong! Am not new to bios. And I said "may"
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 16 at 7:17 PM
$SLS Does Everyone Realize Aza+VEN, BAT for Control Arm Patients, Recently FAILED 3 Large Phase 3 trials? Including Failing the VIALE-M Trial for CR1/ First Remission Maintenance. It is not complicated. GPS is worth a Full $40B + to Big Pharma. A revolutionary, AML Remission Maintenance Immunotherapy, that extends Survival 3X 4X+ with low to No Side Effects, and an Unlimited dosing regime. Gps will Set Records for Patient Uptake rates. FDA/EU Orphan / Fast Track / Rare Priority Review - BLA NOW BEING Prepared. IP Rights Into 2037 - $ABBV $BMY $MRK all Know Gps is the only reason we are seeing Miraculous all Pooled Surivival. BAT/ AZA+VEN RECENTLY FAILED 3 Large Phase 3 Trials for AML Remission Maintenance. it is Not complicated.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 15 at 8:50 PM
$SLS Hope. A beautiful Message of Hope today from our CEO. God Speed and Strength to the entire SLS Community, patients foremost - god bless the 128 Enrolled and 49 who remain, and the Dr's, Clinicians and staff, Steering Committee and IDMC and the entire SLS Corporate Team - and the Inch thick, them too. City of Hope Recruiting AML-MR Patients 35% of AML, at 4 New Locations in Atlanta, Chicago, Phoenix and Los Angeles - Fund managers, discussing SLS / GPS / SLS009 with Angelos will discover these shares stack up to a mountain of Value. 40x + Potential ROI. This AML Platform is for Sale $LLY $PFE $ABBV Gps a Safe AML Remission Maintenance Immunotherapy - Extends OS by Years - and 009 the first On Target CDk9 Inhibitor Fund Managers will continue Feasting on SLS Shares next week after the Conferences.
0 · Reply
TornadoChasers
TornadoChasers May. 15 at 5:44 PM
$ABBV they can buyout so many good ones
0 · Reply
NEWBIGTECH
NEWBIGTECH May. 15 at 5:18 PM
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 15 at 4:41 PM
$SLS $SLS Some (idiots) say, there is No such thing, as a Sure Thing in BIO. It is a Sure thing the Algo's selling SLS Shares Down with the Sanguine Market, Have No Clue SLS is about to Announce the 80th Patient Event. Every one of Us will wish we Owned more of these SLS Shares at $7.00 when the 80th EVENT PR Hits and the Share Price Doubles, Triples or More... -- Here is an Exact Patient Cohort for the REGAL Control Arm - there are No Patients Surviving at ALL Past 16 months. - In other words, not 1 Patient remained Alive at 17 months - Aza+VEN Trial Conducted by one of $ABBV top clinicians. https://haematologica.org/article/view/11910#:~:text=Here%2C%20we%20analyze%20the%20outcomes,on%20salvage%20feasibility%20after%20relapse.
0 · Reply
Latest News on ABBV
AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 8 days ago

AbbVie Transcript: AGM 2026


AbbVie price target raised to $236 from $232 at Evercore ISI

2026-05-04T12:13:35.000Z - 12 days ago

AbbVie price target raised to $236 from $232 at Evercore ISI


AbbVie price target raised to $265 from $262 at Canaccord

2026-04-30T13:31:03.000Z - 16 days ago

AbbVie price target raised to $265 from $262 at Canaccord


AbbVie upgraded to Buy at BofA on durable growth

2026-04-30T10:15:57.000Z - 16 days ago

AbbVie upgraded to Buy at BofA on durable growth


AbbVie upgraded to Buy from Neutral at BofA

2026-04-30T10:14:18.000Z - 16 days ago

AbbVie upgraded to Buy from Neutral at BofA


AbbVie sees Q2 adjusted EPS $3.74-$3.78, consensus $3.74

2026-04-29T16:39:58.000Z - 17 days ago

AbbVie sees Q2 adjusted EPS $3.74-$3.78, consensus $3.74


AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 17 days ago

AbbVie Earnings Call Transcript: Q1 2026


AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 17 days ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth


AbbVie Reports First-Quarter 2026 Financial Results

Apr 29, 2026, 7:47 AM EDT - 17 days ago

AbbVie Reports First-Quarter 2026 Financial Results


US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:19 PM EDT - 23 days ago

US FDA declines to approve AbbVie's wrinkle treatment


Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 14, 2026, 8:50 AM EDT - 4 weeks ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation


AbbVie to Host First-Quarter 2026 Earnings Conference Call

Mar 31, 2026, 8:00 AM EDT - 6 weeks ago

AbbVie to Host First-Quarter 2026 Earnings Conference Call


Buy Or Fear AbbVie Stock At $210?

Mar 19, 2026, 9:26 AM EDT - 2 months ago

Buy Or Fear AbbVie Stock At $210?


AbbVie Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 11:20 AM EDT - 2 months ago

AbbVie Transcript: Leerink Global Healthcare Conference 2026


AbbVie Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 11:10 AM EST - 2 months ago

AbbVie Transcript: TD Cowen 46th Annual Health Care Conference


AbbVie Declares Quarterly Dividend

Feb 19, 2026, 9:37 AM EST - 3 months ago

AbbVie Declares Quarterly Dividend


AbbVie sues US health agency over Botox price controls

Feb 11, 2026, 6:49 PM EST - 3 months ago

AbbVie sues US health agency over Botox price controls


Abbvie sues US health agency over Botox

Feb 11, 2026, 5:13 PM EST - 3 months ago

Abbvie sues US health agency over Botox


AbbVie Earnings Call Transcript: Q4 2025

Feb 4, 2026, 9:00 AM EST - 3 months ago

AbbVie Earnings Call Transcript: Q4 2025


AbbVie Revenue Rises on Immunology Growth

Feb 4, 2026, 8:34 AM EST - 3 months ago

AbbVie Revenue Rises on Immunology Growth


UsingAGodAlgorithm
UsingAGodAlgorithm May. 16 at 10:54 PM
$SE (-75% from short entry) We are the best on ST as far as we have seen. Check our profile We also covered these names. $ABBV $PLTR $MU $MA
0 · Reply
Mike22332233
Mike22332233 May. 16 at 10:51 PM
$SLS Some think $40 Bil BO is silly ... really, FOR AN EFFECTIVE CURE FOR CANCER !!! ... and then across 20 other cancers with WT1 !!! Add in the SLS001 platform!!! ... KEYTRUDA has sales of $34 Bil per year and does NOT cure anything ... We will see how silly it is when $MRK, $ABBV and $PFE are in a bidding war to buy out $SLS ... Single BEST asymmetrical investment idea in my over 40 years investing ... ALL my profits from every other Special Situation Stock I have found (see my other posts) have been plowed back into more SLS ... If you agree with what I will say, then LIKE this and FOLLOW me 👉 @Mike22332233 ...
4 · Reply
Mike22332233
Mike22332233 May. 16 at 9:29 PM
$SLS PART 2 of 2 .. Even with the BAT arm at 14.7 mOS which is almost twice as long as should be expected … EFFECTIVELY, those getting GPS that had an immune response (80% of them) ARE NOT PASSING AWAY!!! ... GAME CHANGING FOR CANCER !!! When the trial ends at the 80th event, I believe you would have ALL 63 in the BAT Control arm passed away, AND ONLY 17 OF THE 63 GPS PATIENTS PASSED AWAY … 46 of the 63 will be alive and living into their 4th yr and some into their 5th year…. This has EFFECTIVELY STOPPED CANCER FROM KILLING THEM IN THIS TYPE OF CANCER !! ... There are an additional 20 or so Cancers with the WT1 within them … as I said before, likely $ABBV or $MEK or $PFE doing a BUY OUT WITHIN 3 months of the readout, and my MAXIMUM PRICE OF $150 to $175 (a $30 to $35 Billion valuation) for the BO may very well be much too low if the HR is GAME-CHANGING at 0.27-0.35 ... if so, expect a bidding war and final BO at $222 !!! ... If you agree then LIKE this and FOLLOW me 👉 @Mike22332233
3 · Reply
DonVigo
DonVigo May. 16 at 7:30 PM
$SLS $ABBV $BMY $MRK 40 billion? You must be brain dead. Is SLS peddling a cure for cancer or a treatment? Outrageous ...!
0 · Reply
DonVigo
DonVigo May. 16 at 7:22 PM
$SLS $ABBV $BMY $MRK That PR event may occur under the name of a different Company. Prove me wrong! Am not new to bios. And I said "may"
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 16 at 7:17 PM
$SLS Does Everyone Realize Aza+VEN, BAT for Control Arm Patients, Recently FAILED 3 Large Phase 3 trials? Including Failing the VIALE-M Trial for CR1/ First Remission Maintenance. It is not complicated. GPS is worth a Full $40B + to Big Pharma. A revolutionary, AML Remission Maintenance Immunotherapy, that extends Survival 3X 4X+ with low to No Side Effects, and an Unlimited dosing regime. Gps will Set Records for Patient Uptake rates. FDA/EU Orphan / Fast Track / Rare Priority Review - BLA NOW BEING Prepared. IP Rights Into 2037 - $ABBV $BMY $MRK all Know Gps is the only reason we are seeing Miraculous all Pooled Surivival. BAT/ AZA+VEN RECENTLY FAILED 3 Large Phase 3 Trials for AML Remission Maintenance. it is Not complicated.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 15 at 8:50 PM
$SLS Hope. A beautiful Message of Hope today from our CEO. God Speed and Strength to the entire SLS Community, patients foremost - god bless the 128 Enrolled and 49 who remain, and the Dr's, Clinicians and staff, Steering Committee and IDMC and the entire SLS Corporate Team - and the Inch thick, them too. City of Hope Recruiting AML-MR Patients 35% of AML, at 4 New Locations in Atlanta, Chicago, Phoenix and Los Angeles - Fund managers, discussing SLS / GPS / SLS009 with Angelos will discover these shares stack up to a mountain of Value. 40x + Potential ROI. This AML Platform is for Sale $LLY $PFE $ABBV Gps a Safe AML Remission Maintenance Immunotherapy - Extends OS by Years - and 009 the first On Target CDk9 Inhibitor Fund Managers will continue Feasting on SLS Shares next week after the Conferences.
0 · Reply
TornadoChasers
TornadoChasers May. 15 at 5:44 PM
$ABBV they can buyout so many good ones
0 · Reply
NEWBIGTECH
NEWBIGTECH May. 15 at 5:18 PM
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 15 at 4:41 PM
$SLS $SLS Some (idiots) say, there is No such thing, as a Sure Thing in BIO. It is a Sure thing the Algo's selling SLS Shares Down with the Sanguine Market, Have No Clue SLS is about to Announce the 80th Patient Event. Every one of Us will wish we Owned more of these SLS Shares at $7.00 when the 80th EVENT PR Hits and the Share Price Doubles, Triples or More... -- Here is an Exact Patient Cohort for the REGAL Control Arm - there are No Patients Surviving at ALL Past 16 months. - In other words, not 1 Patient remained Alive at 17 months - Aza+VEN Trial Conducted by one of $ABBV top clinicians. https://haematologica.org/article/view/11910#:~:text=Here%2C%20we%20analyze%20the%20outcomes,on%20salvage%20feasibility%20after%20relapse.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 15 at 5:39 AM
$SLS $RVMD the IDMC UNBLINDED Phase 3 MOS AND IR DATA FROM THE ACTUAL INTERIM ANALYSIS. MOS and IR DATA that told all those paying attention, Gps is golden - including ABBV and BMY $RHHBY who own Aza Ven, the BAT for Control Patients. - look at the Share price / since the 60th Event was announced Dec 2024.Jan 2025: MCAP up from $77M to 1.29B - Share price up BIGLY - 160 Funds Invested up from 39 ... Look at the share Price since Dec 2025 when the 72nd Event was Announced. The 80th EVENT PR is going to launch this. for those who have no CLUE. BAT - Aza +VEN - Recently FAILED 3 Large Phase 3 Trials for AML Remission conducted by $ABBV. -- LASTLY - the 80th EVENT PR ... Is going to Launch this...
1 · Reply
himsssss
himsssss May. 15 at 5:37 AM
$VKTX Just a little bit longer guys. I heard Brian Lian is getting the deal after $ABBV adds them on myspace or something according to bioloser.
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 15 at 1:01 AM
$SLS Little Known Fact - Gps targets WT1 - an Oncogene expressed in 97% of AML Patients. ALL AML patients regardless of Mutation are Eligible. - 3 Dr's Treating actual Patients are on record stating MOS for patients onBAT is 'dismal, not durable', 'extremely poor - 5-7 months'. - after being asked precisely how long do control patients survive in his clinical practice experience using BAT. " Median OS is just 7 months, 6-8 months. " Using Aza + VEN Aza+VEN BAT recently Failed Large Phase 3 Trials conducted by $ABBV, including 2 Ph 3 Fails for AML Remission Maintenance. VIALE-M FAILED - VIALE-T FAILED - VERONA Failed *source full transcript
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 15 at 12:47 AM
$SLS $RVMD for the INCH THIK MILE WIDE CREW: Gps is worth Tens of Billions. RNPV. Are you so ignorant you don't even know the IDMC UNBLINDED ACTUAL Phase 3 MOS AND IR DATA FROM THE ACTUAL INTERIM ANALYSIS. MOS and IR DATA that told all those paying attention, Gps is golden - including ABBV and BMY $RHHBY who own BAT for Control Patients. - look at the Share price / since the 60th Event was announced Dec 2024.Jan 2025: MCAP up from $77M to 1.29B - Share price up BIGLY - 160 Funds Invested up from 39 ... Look at the share Price since Dec 2025 when the 72nd Event was Announced. The 80th EVENT PR is going to launch this. for those who have no CLUE. BAT - Aza +VEN - Recently FAILED 3 Large Phase 3 Trials for AML Remission conducted by $ABBV. -- LASTLY - the 80th EVENT PR ... Is going to Launch this...
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 14 at 10:34 PM
$SLS focus on actual data / facts. 26 months after enrollment completed, 49 / 50 patients Remain Alive 🙏 Very Ill, Transplant Ineligible Post secondary salvage, AML Cr2 setting where the largest US REGAL clinician is on record saying 'you will not see survival past 12 months'. - 3 Dr's Treating actual Patients are on record stating MOS for patients onBAT is 'dismal, not durable', 'extremely poor - 5-7 months'. MOS and IR data from the actual Interim Analysis - was UNBLINDED. Industry Players accumulating Know. Most of the 49 or 50 REGAL Phase 3 Patients, who remain continue receive GPS Immunotherapy. - after being asked precisely how long do control patients survive in his clinical practice experience using BAT. " Median OS is just 7 months, 6-8 months. " Using Aza + VEN Aza+VEN BAT recently Failed Large Phase 3 Trials conducted by $ABBV, including 2 Ph 3 Fails for AML Remission Maintenance. VIALE-M FAILED - VIALE-T FAILED - VERONA Failed *source full transcript
0 · Reply
Wallst45
Wallst45 May. 14 at 9:47 PM
$ABBV nice chart 📊
0 · Reply
Iceman467
Iceman467 May. 14 at 8:32 PM
$ABBV drip tomorrow
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 14 at 6:42 PM
$SLS $LLY $ABBV BALLISTIC VERTICALITY --- in Count Down Mode. --- 80th Event may have already occurred, waiting to cycle through the data collection process. - Registrational Phase 3 Results will give Gps the Fda Green light to Generate Billions in Real Revenue Each Year - Billions of Dollars that are worth Several Tens of Billions to Big Pharma - $LLY $PFE Gps Immunotherapy will set records for patient uptake rates, 3x 4x OS Benefit for 100,000 AML Patients Currently in Remission. - Pristine Safety Profile - Easy to administer / manufacture, high margin - FDA/EU Orphan / Fast Track RPRD +200M CASH - IP Rights into 2037.
2 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 14 at 4:50 PM
$SLS $RVMD FREE MONEY. Anyone INVESTING NOW ahead of the 80th EVENT is GUARANTEED Profit. The Share Price Will be climbing a $40B Mountain of Value - until it Absolutely Launches when we get the 80th Event PR. A SURE THING WINNER - massive Catalyst to Followed by Final Results Giving Gps the FDA Green Light to Generate Tens of Billions of Dollars - Tens of Billions in Real Revenue worth $40B to $LLY $ABBV - this $1.2B Manipulated Equity is worth $40B the Instant P3 Data Hits
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 14 at 4:42 PM
$SLS FREE MONEY. Anyone Selling Shares Prior to the 80th EVENT is GIVING AWAY FREE MONEY. The Share Price Will be climbing a Mountain of Value - until it Absolutely Launches when we get the 80th Event PR. A SURE THING WINNER - massive Catalyst to Followed by Final Results Giving Gps the FDA Green Light to Generate Tens of Billions of Dollars - Tens of Billions in Real Revenue worth $40B to $LLY $ABBV - this $1.2B Manipulated Equity is worth $40B the Instant P3 Data Hits
2 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 14 at 4:27 PM
$SLS The Price will certainly Launch with the 80th Event PR … a 100% Sure thing Guaranteed Win. $RVMD added $15B in market value in the 2 days after announcing their P3 Trial results. - something similar is about to happen here - Many Institutions will discover this next week. The Phase 3 Result will give Gps the FDA green light to treat 100,000 AML Patients Currently in Remission and another 40,000 or so Each Year. xCCO Estimated $300K Minimum Rev per patient Year 1. Infinite Dosing to Relapse - 2 -5 year Rev Per Patient. $28 B Total Addressable Market - worth Every Nickel of $40B to $LLY $ABBV $MRK ---
0 · Reply
scalesojustice
scalesojustice May. 14 at 3:57 PM
$SLS $ABBV up 11 pts this week....perfect time for the wedding
0 · Reply